कंपनी का अवलोकन
BioAtla, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing specific and selective antibody-based therapeutics designed for the treatment of solid tumor cancer. The company functions within the healthcare sector, specifically under the biotechnology industry, where innovation in drug development and clinical trials defines its operational landscape. With a market capitalization of $7.49M and a workforce of 41 employees, the organization maintains a small-scale presence typical of early-stage biotech entities. The annual revenue of $2.00M over the trailing twelve months indicates that the company is in a revenue-generating but pre-profitability phase, suggesting its market position is currently defined by product candidate development rather than established commercial dominance. This limited market cap and modest revenue stream reflect the high-risk, high-reward nature of the biotechnology sector, where significant capital is often required before products reach widespread market availability. The small employee count further underscores the company's focus on lean operational structures to manage costs during the clinical development stages of its lead products.
वित्तीय स्वास्थ्य
BioAtla, Inc. reported a revenue of $2.00M for the trailing twelve months, yet this generated a net income of $-59,607,000, revealing a substantial disconnect between top-line sales and bottom-line profitability. The EBITDA stands at $-58,332,000, which highlights that the company's cost structure involves significant expenditures in research and development that far exceed current revenue generation. The free cash flow is reported at $-22,801,624, indicating that the company is consuming cash reserves to fund its operations and product development efforts rather than generating excess liquidity. Analysis of the margins shows a gross margin of 0.0%, an operating margin of -462.8%, and a profit margin of 0.0%, all of which point to extreme operational inefficiency relative to sales or significant upfront costs not yet amortized against revenue. The company holds $7.12M in cash against $6.20M in debt, resulting in a debt-to-equity ratio of N/A, which suggests the balance sheet relies heavily on equity financing or has negligible equity due to accumulated losses. The current ratio of 0.37 indicates that the company possesses less than half of its current liabilities in liquid assets, signaling potential short-term liquidity constraints. Return on Equity is listed as N/A due to the lack of positive equity, while the Return on Assets is -110.8%, demonstrating that the assets are currently generating negative returns for the company.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is N/A because the company has not generated positive earnings, while the forward P/E is -3.38, implying that the market anticipates a continued path to profitability or a specific earnings turnaround scenario before traditional valuation metrics become applicable. The price-to-book ratio stands at -7.47, which indicates that the market values the company at a significant premium over its book value in terms of absolute magnitude, though the negative figure reflects the company's accumulated net losses and negative equity position. The price-to-sales ratio is 3.74, and the EV/EBITDA is -0.11; these alternative metrics suggest that investors are pricing the stock based on its potential future clinical success rather than current financial performance. The 52-week high is $71.50 and the 52-week low is $4.35, meaning the current trading price sits significantly below the yearly peak and within the lower volatility range of its trading history. The beta value of 1.21 indicates that the stock's price volatility is 21% higher than the broader market, reflecting the heightened risk associated with clinical-stage biotechnology investments.
Growth & Income
The revenue growth year-over-year is listed as N/A, and the earnings growth year-over-year is also N/A, indicating that the company is too early in its lifecycle to establish a consistent historical growth trajectory for comparison. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, which means the firm reinvests all available resources into advancing its clinical pipeline and operational capabilities rather than distributing income to shareholders. The absence of dividend payouts is a strategic choice common in the biotechnology sector, where capital retention is essential for funding expensive drug trials and regulatory processes. Overall, the growth and income profile of BioAtla, Inc. is characterized by a complete focus on capital appreciation potential through product development, with no current income generation mechanisms available to investors.